63411-87-0

Basic information

• Product Name: 1-(2,4-DIHYDROXY-5-PROPYLPHENYL)ETHAN-1-ONE
• Synonyms: 1-(2,4-DIHYDROXY-5-PROPYLPHENYL)ETHAN-1-ONE;1-(2,4-dihydroxy-5-propylphenyl)ethanone
• CAS NO: 63411-87-0
• Molecular Formula: C₁₁H₁₄O₃
• Molecular Weight: 194.23
• Product Categories: Phenyls & Phenyl-Het;Phenyls & Phenyl-Het
• Mol File: 63411-87-0.mol
• Article Data: 2

Chemical Properties

• Melting Point: 99 °C
• Boiling Point: 359.1°C at 760 mmHg
• Flash Point: 185.1°C
• Appearance: /
• Density: 1.162g/cm³
• Vapor Pressure: 1.18E-05mmHg at 25°C
• Refractive Index: 1.562
• PKA: 8.49±0.23(Predicted)
• CAS DataBase Reference: 1-(2,4-DIHYDROXY-5-PROPYLPHENYL)ETHAN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2,4-DIHYDROXY-5-PROPYLPHENYL)ETHAN-1-ONE(63411-87-0)
• EPA Substance Registry System: 1-(2,4-DIHYDROXY-5-PROPYLPHENYL)ETHAN-1-ONE(63411-87-0)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 63411-87-0(Hazardous Substances Data)

Usage

Preparation

Preparation by reaction of acetic acid on 4-propylresorcinol with zinc chloride (Nencki reaction).

InChI:InChI=1/C11H14O3/c1-3-4-8-5-9(7(2)12)11(14)6-10(8)13/h5-6,13-14H,3-4H2,1-2H3

Upstream product

• 18979-60-7 4-propylresorcinol 
• 75-05-8 acetonitrile 
• 108-46-3 recorcinol 
• 5792-36-9 2',4'-dihydroxypropiophenone 
• 75-36-5 acetyl chloride 
• 64-19-7 acetic acid 

Downstream Products

• 81468-78-2 2-ethoxy-4-methoxy-5-propylacetophenone oxime 
• 81468-75-9 2-ethoxy-4-methoxy-5-propylacetophenone 
• 72018-35-0 4-methoxy-2-hydroxy-5-propylacetophenone 
• 90547-04-9 2,4-diethoxy-5-n-propylacetophenone 

Relevant articles and documents

Discovery and SAR study of hydroxyacetophenone derivatives as potent, non-steroidal farnesoid X receptor (FXR) antagonists

Compound 1 (IC50 = 35.2 ± 7.2 μM), a moderate FXR antagonist was discovered via high-throughput screening. Structure-activity relationship studies indicated that the shape and the lipophilicity of the substituents of the aromatic ring affect the activity dramatically, increasing the shape and the lipophilicity of the substituents of the aromatic ring enhances the potency of FXR antagonists. Especially, when the OH at C2 position of the aromatic ring was replaced by the OBn substituent (analog 2b), its activity could be improved to IC50 = 1.1 ± 0.1 μM. Besides, the length of the linker and the tetrazole structure are essential for retaining the activity.